paion.com
Get leads like Paion — and thousands more
Build targeted lists by tech stack, traffic, and more
Paion: The $5.8M Pharma Pioneer Betting on Sedation
A lean German biotech betting big on a single compound in a crowded market.
In the high-stakes world of pharmaceutical development, Paion AG isn't chasing a portfolio of miracles; they are betting their entire company on a single molecule: remimazolam. This isn't a sprawling conglomerate; it's a surgical strike on the sedation market, headquartered in Aachen with a skeleton crew of just 29 employees.
"Paion isn't playing the volume game; they are playing the precision game, targeting a specific procedural sedation niche with an ultra-short-acting compound."
The Remimazolam Gamble
Paion’s entire narrative revolves around remimazolam, an IV benzodiazepine designed for procedural sedation. The data reveals a company in 'final stage' development in the U.S. while simultaneously planning Phase III trials in the EU for general anesthesia. This dual-track approach on a single asset is high-risk, high-reward. With only $5.8M in revenue, they are burning cash to clear regulatory hurdles.
The Transatlantic Split
Paion’s strategy is geographically bifurcated. In the U.S., the focus is strictly on procedural sedation—a massive outpatient market. In Japan, they’ve already completed a full clinical program for general anesthesia. The EU remains a battleground where they plan to launch a Phase III trial. This fragmented roadmap suggests a reactive strategy, capitalizing on regional regulatory differences rather than a unified global rollout.
The traffic data paints a picture of a company flying under the radar. With a global rank of #8.3M and only 2,040 monthly visits, Paion is virtually invisible to the general public. Their audience is niche, likely investors and industry insiders searching specifically for 'Paion' or 'Frankfurt stock exchange ticker.' The lack of organic keyword dominance outside their brand name indicates a severe underinvestment in digital presence or a deliberate strategy to fly low until commercial launch.
- Hyper-focused pipeline: 90% of resources tied to remimazolam.
- Lean operations: 29 employees generating $5.8M in revenue (approx. $200k/employee).
- Tech stack modernity: Uses Tailwind CSS and Bootstrap, suggesting a functional but non-cutting-edge web presence.
- Traffic opacity: 55% of traffic is undefined/geo-ambiguous, hinting at bot traffic or poor analytics tracking.
The Verdict: A Sleeper Pick or a Stalled Engine?
Paion represents the classic biotech paradox: massive potential wrapped in a quiet shell. For investors, the low web traffic is a feature, not a bug—it suggests the market hasn't priced in the value of remimazolam yet. For founders, it’s a lesson in extreme focus. They aren't trying to be everything to everyone; they are trying to be the gold standard for sedation, one procedure at a time.
What tech stack does Paion use?
How much traffic does Paion get?
Traffic & Engagement
Traffic Sources
Where is Paion's audience located?
What keywords does Paion rank for?
5 keywordsHow is Paion's SEO?
Meta Tags
Paion
PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in the final stage of clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its development program in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anesthesia was completed in Japan. In the EU, PAION is currently planning to continue the clinical development program by starting a Phase III trial in the second half of 2018. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer" in sedation and anesthesia.
H1 Tags
What is Paion's revenue?
Who works at Paion?
Loading leads...
What do customers think of Paion?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Paion
What is Paion's Revenue?
What does Paion do?
How fast is Paion growing?
What technologies does Paion use?
Who are Paion's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Paion?
Social Profiles
Contact Information
Export paion.com Data
Download the complete tech stack, analytics, leads, and company data for paion.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About paion.com
PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in the final stage of clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its development program in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anesthesia was completed in Japan. In the EU, PAION is currently planning to continue the clinical development program by starting a Phase III trial in the second half of 2018. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer" in sedation and anesthesia.
Company Overview
paion.com Social Media
Contact paion.com
Email Addresses
Phone Numbers
Technology Stack
paion.com uses 7 technologies across their website including Lazy Loading, Twitter Cards, DaisyUI, and more.
Performance
Lazy Loading
Web Standards
Twitter Cards
UI Libraries
DaisyUI
CSS Frameworks
Bootstrap, Tailwind CSS
JavaScript Libraries
Slick, jQuery
Traffic & Audience
paion.com receives approximately 2.0K monthly visitors and ranks #8,310,162 globally. The website has a bounce rate of 43% with visitors viewing an average of 1.5 pages per visit. Users spend an average of 0:05 on the site.
The majority of paion.com's traffic comes from undefined, .
Frequently Asked Questions
What is paion.com?
What technologies does paion.com use?
How do I contact paion.com?
What are paion.com's social media accounts?
How popular is paion.com?
Related Searches
This page provides publicly available information about paion.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit paion.com directly at https://paion.com.